Lars Fruergaard Jorgensen became Novo Nordisk CEO in 2017 as sales were flat

Lars Fruergaard Jorgensen became chief executive officer of Novo Nordisk in 2017, taking over a company whose net sales were essentially flat year over year at DKK 111.7 billion, with operating profit of DKK 49.0 billion ^[1]. The same year, Ozempic, a once-weekly semaglutide injection, was approved in the United States ^[1].

Novo Nordisk reports its results in Danish kroner and files an annual report with the U.S. Securities and Exchange Commission on Form 20-F, the document used by foreign companies whose shares trade in the United States ^[1]. The figures describe a business whose top line was not growing at the moment the leadership changed: net sales of DKK 111.7 billion, essentially unchanged from the year before, and operating profit of DKK 49.0 billion ^[1].

The annual report identifies Ozempic as a semaglutide product approved in the U.S. market that year, but it does not break out how much revenue the drug produced in 2017, its first partial year on sale ^[1]. A separate U.S. sales figure for Ozempic's launch year has not been reported in the filing ^[1].

The document records the change in executive management but does not describe the board's reasons for choosing Jorgensen, or any strategic plans he announced at the time. Those details have not been disclosed ^[1].

For context on the numbers, DKK 111.7 billion and DKK 49.0 billion are company-wide totals covering every Novo Nordisk product, not just GLP-1 medicines. In 2017 the company's portfolio included established treatments for diabetes and other conditions, and Ozempic was a new addition rather than an established revenue driver ^[1]. How large a role the drug would eventually play in the company's results was not known when it was approved, and the report contains no forecast for the product ^[1].

Why it matters for patients

Novo Nordisk is the manufacturer of Ozempic, so the person running the company sets priorities for research, manufacturing capacity and pricing. A change at the top can shift those priorities over time, although the filing does not describe any specific direction Jorgensen set when he took over ^[1].

Ozempic has been available in the United States since 2017 ^[1]. That means patients who began the weekly semaglutide injection early have now been on it for several years, and anyone considering it is looking at a medicine with a long U.S. market history rather than a new launch. Whether a particular patient can get the drug and what it costs them depends on supply and insurance coverage, which are shaped by the manufacturer's commercial decisions as well as by the drug itself.

The 2017 backdrop is also a reminder that Ozempic's approval came at a moment when Novo Nordisk's overall revenue was not expanding ^[1]. A drug's approval and its commercial scale are separate events, and the filing shows only the first of those for Ozempic in 2017.

Readers who want the company's own account of that year can find the net sales figure, the operating profit figure and the Ozempic approval described in the annual report Novo Nordisk filed with the SEC ^[1].